DelveInsight’s, “Epidermolysis Bullosa Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including Epidermolysis Bullosa clinical trials and nonclinical stage products. It also covers the Epidermolysis Bullosa therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Epidermolysis Bullosa Pipeline Report

• DelveInsight’s Epidermolysis Bullosa pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Epidermolysis Bullosa treatment.
• The leading companies working in the Epidermolysis Bullosa Market include Abeona Therapeutics, Castle Creek Biosciences, RHEACELL, Aegle Therapeutics, Phoenix Tissue Repair Inc., Lenus Therapeutics LLC, Wings Therapeutics Inc., Krystal Biotech Inc., Onconova Therapeutics Inc., InMed Pharmaceuticals Inc., Constant Therapeutics, Kangstem Biotech, ProQR Therapeutics, Ishin Pharmaceutical, and others.
• Promising Epidermolysis Bullosa Pipeline Therapies in the various stages of development include SD-101-6.0 cream, diacerein 1% ointment, allo-APZ2-OTS, PTR-01, Oleogel-S10, FCX-007, and others.
• August 2023: Anterogen Co. Ltd announced a study of phase 1 & 2 clinical trials for Allogeneic mesenchymal stem cells and Polyurethene Film. This is a phase I/II open-label study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Dystrophic Epidermolysis Bullosa.
• September 2023: BioMendics LLC announced a study of phase 1 clinical trials for TolaSure Topical Gel and Vehicle Topical Gel. TolaSure is a topical gel for the promotion of accelerated wound healing. This Phase I study will assess the safety, tolerability, and clinical effects of TolaSure when applied to wounded skin areas of patients diagnosed with severe epidermolysis bullosa simplex (i.e., EBS-Dowling Meara). A total of 10, severe EBS patients, males and females ages 18 years and older, will be enrolled.

 

Request a sample and discover the recent advances in Epidermolysis Bullosa Treatment Drugs @ Epidermolysis Bullosa Pipeline Report

 

In the Epidermolysis Bullosa pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Epidermolysis Bullosa clinical trials studies, Epidermolysis Bullosa NDA approvals (if any), and product development activities comprising the technology, Epidermolysis bullosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Epidermolysis Bullosa Overview

Epidermolysis bullosa (EB) is a genetic skin disorder characterized clinically by blister formation from mechanical trauma. There are four main types with additional sub-types identified. There is a spectrum of severity, and within each type, one may be either mildly or severely affected.

 

Find out more about Epidermolysis Bullosa Therapeutics Assessment @ Epidermolysis Bullosa Preclinical and Discovery Stage Products

 

Epidermolysis Bullosa Emerging Drugs Profile

• EB-101: Abeona Therapeutics
• D-Fi (FCX-007): Castle Creek Biosciences

 

Epidermolysis Bullosa Pipeline Therapeutics Assessment

 There are approx. 20+ key companies which are developing the Epidermolysis Bullosa therapies. The Epidermolysis Bullosa companies which have their Epidermolysis Bullosa drug candidates in the most advanced stage, i.e. phase III include, Abeona Therapeutics.

 

Learn more about the emerging Epidermolysis Bullosa Pipeline Therapies @ Epidermolysis Bullosa Clinical Trials Assessment

 

Scope of the Epidermolysis Bullosa Pipeline Report

• Coverage- Global
• Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Epidermolysis Bullosa Companies- Abeona Therapeutics, Castle Creek Biosciences, RHEACELL, Aegle Therapeutics, Phoenix Tissue Repair Inc., Lenus Therapeutics LLC, Wings Therapeutics Inc., Krystal Biotech Inc., Onconova Therapeutics Inc., InMed Pharmaceuticals Inc., Constant Therapeutics, Kangstem Biotech, ProQR Therapeutics, Ishin Pharmaceutical, and others.
• Epidermolysis Bullosa Pipeline Therapies- SD-101-6.0 cream, diacerein 1% ointment, allo-APZ2-OTS, PTR-01, Oleogel-S10, FCX-007, and others.

 

Dive deep into rich insights for new drugs for Epidermolysis Bullosa treatment, Visit @ Epidermolysis Bullosa Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Epidermolysis bullosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. EB-101: Abeona Therapeutics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. PTR-01: Phoenix Tissue Repair
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I/II)
13. Drug Name: Product Name
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. TXA127: Constant Therapeutics
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Epidermolysis bullosa Key Companies
20. Epidermolysis bullosa Key Products
21. Epidermolysis bullosa- Unmet Needs
22. Epidermolysis bullosa- Market Drivers and Barriers
23. Epidermolysis bullosa- Future Perspectives and Conclusion
24. Epidermolysis bullosa Analyst Views
25. Epidermolysis bullosa Key Companies
26. Appendix

 

For further information on the Epidermolysis Bullosa pipeline therapeutics, reach out to Epidermolysis Bullosa Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking